logo

Seattle Genetics Inc. (SGEN)



Trade SGEN now with
  Date
  Headline
2/16/2018 8:02:42 AM Seattle Genetics Gets US Regulatory Approval For Proposed Acquisition Of Cascadian Therapeutics
2/9/2018 6:45:57 AM Seattle Genetics And Pieris Pharma Announce Multi-Program Immuno-Oncology Collaboration
2/8/2018 5:40:05 PM Seattle Genetics Begins Tender Offer For Cascadian Therapeutics
2/6/2018 4:04:40 PM Seattle Genetics Q4 Loss Per Share $0.41 Vs Loss $0.39 Last Year
2/1/2018 6:32:14 AM Seattle Genetics Announces Pricing Of Public Offering Of 11.54 Mln Shares At $52/Shr
1/31/2018 6:40:52 AM Seattle Genetics Begins Underwritten Public Offering Of $550.0 Mln Shares
1/31/2018 6:31:19 AM Seattle Genetics To Acquire Cascadian Therapeutics For $10/Shr Cash, Or Approx $614 Mln
1/22/2018 8:05:01 AM Seattle:ADCETRIS Gets EC Approval For CD30-Positive Cutaneous T-Cell Lymphoma After At Least One Prior Systemic Therapy
1/8/2018 8:07:56 AM Eattle Genetics Highlights Leadership In Expanding Field Of Antibody-Drug Conjugates
1/2/2018 8:03:46 AM Seattle Genetics : FDA Accepts SBLA And Grants Priority Review For ADCETRIS In Frontline Advanced Hodgkin Lymphoma
12/7/2017 8:03:05 AM Seattle Genetics Presents Updated Phase 1 Data For Ladiratuzumab Vedotin In Patients With Triple Negative Breast Cancer
11/8/2017 8:08:13 AM Seattle Genetics, Astellas Initiate Phase 1b Trial Of Enfortumab Vedotin In Combination With Immune Checkpoint Inhibitor